Printer Friendly
The Free Library
19,595,263 articles and books
Member login
User name  
Password 
 
Join us Forgot password?

ArQule to Present at BIO CEO & Investor Conference 2007 on February 14, 2007.


Live Webcast Scheduled for 1:30 P.M. Eastern Time

WOBURN, Mass. -- ArQule, Inc. (NASDAQ NASDAQ
 in full National Association of Securities Dealers Automated Quotations

U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on
: ARQL) today announced that it will present at the BioCEO & Investor Conference on Wednesday, February 14, 2007 at 1:30 p.m. eastern time. ArQule's presentation will be webcast live and can be accessed through the investor relations section of the Company's website. The conference will be held at the Waldorf Astoria Hotel, New York City New York City: see New York, city.
New York City

City (pop., 2000: 8,008,278), southeastern New York, at the mouth of the Hudson River. The largest city in the U.S.
.

About ArQule

ArQule, Inc. is a biotechnology company engaged in the research and development of next-generation, small-molecule cancer therapeutics. The Company's targeted, broad-spectrum products and research programs are designed to affect key biological processes that are central to cancer. ArQule's lead clinical-stage products have been generated from two scientific platforms: Cancer Survival Protein modulation and Activated Checkpoint Therapy([R]) (ACT). The Cancer Survival Protein modulation platform has generated a clinical-stage product designed to inhibit a molecule known as c-Met, which plays multiple roles in cancer cell growth, survival, invasion, angiogenesis angiogenesis /an·gio·gen·e·sis/ (-jen´e-sis) vasculogenesis; development of blood vessels either in the embryo or in the form of neovascularization or revascularization.

an·gi·o·gen·e·sis
n.
 and metastasis metastasis /me·tas·ta·sis/ (me-tas´tah-sis) pl. metas´tases  
1. transfer of disease from one organ or part of the body to another not directly connected with it, due either to transfer of pathogenic microorganisms or to
. The ACT platform is designed to kill cancer cells selectively while sparing normal cells through direct activation of DNA DNA: see nucleic acid.
DNA
 or deoxyribonucleic acid

One of two types of nucleic acid (the other is RNA); a complex organic compound found in all living cells and many viruses. It is the chemical substance of genes.
 damage response/checkpoint pathways. The Company's lead ACT program, based on the E2F-1 pathway, is partnered with Roche. For more information, please visit www.arqule.com.
COPYRIGHT 2007 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2007, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Feb 8, 2007
Words:208
Previous Article:Todd Shipyards Corporation Announces Quarterly Financial Results for December 31, 2006.
Next Article:'Bear Belly Baby Pool' Gets Fans Back in the Game.
Topics:



Related Articles
ArQule Initiates Phase 1 Trial with ARQ 171, Provides Enrollment Update on ARQ 501 and ARQ 197.
ArQule Provides Clinical Trial Update.
Therapeutic Workshop Topics for BIO CEO & Investor Conference 2007 Now Available Online.
ArQule, Inc. to Report Fiscal 2006 Financial Results on February 8, 2007.
Top Industry And Financial Leaders to Explore Key Business Issues Impacting The Biotech Industry At BIO's CEO & Investor Conference.
ArQule Announces Acceptance of Clinical Data on ARQ 197, c-Met Inhibitor, for Oral Presentation at ASCO.
ArQule to Present at CIBC Annual Biotechnology & Specialty Pharmaceuticals Conference on April 11, 2007.
ArQule Summarizes Abstracts Presented At AACR.
ArQule to Present at Fortis Biotechnology Conference on April 25, 2007.
ARQULE/KYOWA HAKKO KOGYO SIGN ARQ 197 ASIA LICENSE.

Terms of use | Copyright © 2012 Farlex, Inc. | Feedback | For webmasters | Submit articles